TAINAN, October 15, 2014 /PRNewswire/ — ScinoPharm (TWSE:1789) announced that it was named the “Active Pharmaceutical Ingredient (API) Supplier of the Year” at the Global Generics and Biosimilars Awards co-hosted by Generics bulletin and Ark Patent Intelligence. The award recognizes excellent performance across a range of business activities and was won in strong competition against a number of leading Pharmaceutical companies including Dr. Reddy’s, Teva, Perrigo, Unichem, etc.
The awards are open to companies directly involved in developing, authorizing, marketing and distributing bioequivalent generics or biosimilars. With almost 100 company nominations, expert independent judges voted for award winners based on recent overall performance and achievements obtained from publicly-available information. The judging panels comprise both independent generics and biosimilars industry experts and authorities in the disciplines involved including the former global heads of well-known pharmaceutical companies like Actavis and Ratiopharm.
Dr. Yung-Fa Chen, President and CEO of ScinoPharm said, “ScinoPharm is a trendsetter as the first ever API supplier selected for this award. We will strive to maintain our expertise and market leadership in high-potent APIs and collaborate with customers to forge closer bonds and reap the rewards of growth together.”
“We were happy to sponsor the first ever API supplier of the year award,” said Kate Kuhrt, senior director of Generics Content Strategy at Thomson Reuters. “Generic companies throughout the world use Thomson Reuters Newport on a daily basis to source active ingredients. So we know and value the importance of the API. Without access to high quality active ingredients, it is impossible to develop safe and effective generic therapies.”
The Global Generics & Biosimilars Awards recognize the best companies in the global generics and biosimilars field in 11 categories: Company of the Year; Company of the Year – Americas; Company of the Year – Asia-Pacific; Company of the Year – EMEA; Leader of the Year; Innovation of the Year; Biosimilar Initiative of the Year; API Supplier of the Year; Acquisition of the Year; Business Development of the Year; and Patent Litigation of the Year.
ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With research and manufacturing facilities in both Taiwan and China, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. The Company also provides a vertically integrated, one-stop-shopping service for drug product customers by expanding into the field of oncological injectable formulations. For more information, please visit the Company’s website at http://www.scinopharm.com